Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide Orodispersible Tablets in Adults With Eosinophilic Esophagitis
NCT06596252Phase 3Active, not recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- May 2021
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of EPI-EE in eosinophilic esophagitis (EoE), sponsored by Dr. Falk Pharma GmbH. Started May 2021; status: active, not recruiting.
02
Drugs
EPI-EE
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT06596252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06596252.